Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Bayer
Sort By
Newest First
1 / 2
1 / 2
Strategic Collaboration
Bayer and Atara Biotherapeutics Enter Strategic Collaboration for Mesothelin-Targeted CAR T-cell Therapies for Solid Tumors
Bayer
PR-M11-20-030
Dec 10, 2020
M&A
Bayer Acquires AskBio to Broaden Innovation Base in Cell and Gene Therapy
Bayer
PR-M10-20-15
Oct 27, 2020
CRO
Bayer and Nuvisan Create New Research Unit in Berlin
Bayer
PR-M02-20-NI-013
Feb 13, 2020
M&A
Wuxi Biologics and Bayer Enter into an Acquisition Agreement on a Drug Product Plant in Germany
WuXi Biologics
PR-M01-20-NI-025
Jan 16, 2020
M&A
Yellow Wood Partners to Acquire Iconic Dr. Scholl’s™ Brand from Bayer
Bayer
PR-M07-19-NI-065
Jul 25, 2019
Recall
Bayer Statement on Voluntary Recall of Two Lots of Kogenate® FS Antihemophilic Factor (Recombinant) in the United States
Nice Insight
PR-M07-19-NI-062
Jul 24, 2019
FDA Approval
FDA Approves Bayer's Gadavist® (gadobutrol) Injection as the First and Only Contrast Agent for Use in Cardiac MR for Coronary Artery Disease
Bayer
PR-M07-19-NI-040
Jul 16, 2019
Announcement
Bayer Supervisory Board Takes Action to Address the Glyphosate Litigation and Welcomes the Appointment of Ken Feinberg as Mediator
Bayer
PR-M07-19-NI-009
Jul 05, 2019
Collaboration
Bayer and Foundation Medicine Announce Global Collaboration to Develop Next-Generation Sequencing (NGS)-based Companion Diagnostics in Oncology
Bayer
PR-M05-19-NI-078
May 29, 2019
Investment
Bayer Invests $150 Million to Build New Cell Culture Technology Center in Berkeley to Spur Innovation of Biotech Therapies
Bayer
PR-M05-19-NI-040
May 14, 2019
Oncology
Bayer Announces Results of Sub-group Analysis for Vitrakvi® (larotrectinib) in Patients with NTRK Gene Fusion-Positive Metastatic Non-small Cell Lung Cancer (NSCLC)
Bayer
PR-M04-19-NI-047
Apr 15, 2019
Corporate Culture
Bayer Only Life Science Company Named as a Most Reputable Company in Biggest-Ever Corporate Reputation Study in U.S.
Bayer
PR-M04-19-NI-036
Apr 10, 2019
Oncology
Bayer to Obtain Full Rights to Global Development and Commercialization of Oncology Compounds Vitrakvi® (larotrectinib) and BAY 2731954 (LOXO-195)
Bayer
PR-M02-19-NI-040
Feb 19, 2019
Veterinary
Bayer Introduces Versatile New Option for Heartworm Prevention and Intestinal Parasite Control
Bayer
PR-M01-19-NI-062
Jan 22, 2019
Prescribing Information
Bayer Updates Betaseron (interferon beta-1b) Prescribing Information in Accordance with the U.S. Food and Drug Administration's Pregnancy and Lactation Labeling Rule
Bayer
PR-M01-19-NI-004
Jan 02, 2019
Cutbacks and Divestitures Planned at Bayer
Nice Insight
PAO-M12-18-NI-004
Dec 05, 2018
FDA Approval
FDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion(1,2)
Bayer
PR-M11-18-NI-104
Nov 29, 2018
Appointment
Bayer appoints Sebastian Guth to lead Pharmaceuticals business in the Americas
Bayer: Science For A Better Life
PR-M10-18-NI-015
Oct 03, 2018
Drug Development
Bayer Gets FDA Approval for Hemophilia A Drug
Emilie Branch
Pharma's Almanac
PAO-M09-18-NI-006
Sep 06, 2018
Partnership
Broad and Bayer Expand Partnership, Launching New Research Effort to Develop Therapies for Heart Failure
Bayer
PR-M07-18-NI-005
Jul 02, 2018
